Incyte Corp at Evercore ISI HealthCONx Conference (Virtual) Transcript

Nov 29, 2022 / 05:35PM GMT
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst

All right. Welcome, everyone. This is Gavin Clark-Gartner from the Evercore ISI Biotech research team, and I'm very happy to be here with the team from Incyte. We have Herve Hoppenot, the Chairman and CEO; Christiana Stamoulis, CFO; and Jim Lee, who is the Head of Information and Autoimmunity Development. Thanks so much for joining us.

Herve Hoppenot - Incyte Corporation - Chairman, President & CEO

Thank you for having us.

Questions and Answers:

Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst

Yes, absolutely. So we have 20 minutes for our fireside. So we're going to jump right into some more specific question and answers. And maybe the point to start is actually with the Inflation Reduction Act. And first, I just wanted to confirm you have met the small biotech exemption criteria, correct, for -- [at least for Jakafi]. So negotiated price couldn't go
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot